Azacitidine plus venetoclax in high-risk myelodysplastic syndromes, post-CAR T-cell hematotoxicity in B-cell acute lymphoblastic leukemia (B-ALL), and inotuzumab ozogamicin resistance in B-ALL

Explore the promising combination of azacitidine and venetoclax for treating high-risk myelodysplastic syndromes. Discover a cutting-edge risk-scoring system that predicts hematotoxicity after CAR T-cell therapy in B-cell acute lymphoblastic leukemia (B-ALL). Additionally, learn about the fascinating mechanisms behind inotuzumab ozogamicin resistance, highlighting the DNTT gene's role as a potential biomarker for treatment challenges. This deep dive into hematologic treatments offers insight into the future of cancer care.